The dual neuroprotective-neurotoxic profile of cannabinoid drugs

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1391-1401

  Sarne, Yosef ^a   Asaf, Fadi ^a   Fishbein, Miriam ^a   Gafni, Mikhal ^a   Keren, Ora ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

carbon monoxide intoxication; neuroprotection; postconditioning; preconditioning; PTZ (pentylenetetrazole); seizures; THC ( 9 tetrahydrocannabinol)

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 HYDROXYMETHYLINDANYL 4 OXY)PHENYL 4,4,4 TRIFLUORO 1 SULFONIC ACID; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; BAY 387271; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; DRONABINOL; MITOGEN ACTIVATED PROTEIN KINASE 1; RIMONABANT; UNCLASSIFIED DRUG; BAY 38 7271; CANNABINOID; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPROTECTIVE AGENT;

ANALGESIA; APOPTOSIS; BRAIN DAMAGE; BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CELL DEATH; CELL SURVIVAL; COGNITION; COGNITIVE DEFECT; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME ACTIVATION; EXCITOTOXICITY; FEVER; HYPERTHERMIA; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; LOCOMOTION; LOW DRUG DOSE; MAZE TEST; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NEUROTOXICITY; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SINGLE DRUG DOSE; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY; ADVERSE OUTCOME; BRAIN EDEMA; BRAIN INFARCTION; CELL VIABILITY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENZYME PHOSPHORYLATION; HUMAN; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEARNING DISORDER; LONG TERM EXPOSURE; MEMORY DISORDER;

ANIMALS; BRAIN; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES;

EID: 79960332482     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01280.x     Document Type: Review

References (137)

1. Abood ME, Rizvi G, Sallapudi N, McAllister SD, (2001). Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309: 197-201. (Pubitemid 32763173)
2. Agell N, Bachs O, Rocamora N, Villalonga P, (2002). Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal 14: 649-654. (Pubitemid 34518618)
3. Amal H, Fridman-Rozevich L, Senn R, Strelnikov A, Gafni M, Keren O, et al,. (2010). Long-term consequences of a single treatment of mice with an ultra-low dose of Delta9-tetrahydrocannabinol (THC). Behav Brain Res 206: 245-253.
4. Ameri A, (1999). The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348. (Pubitemid 29230000)
5. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT, (2008). Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 41: 1067-1074.
6. Assaf F, Fishbein M, Gafni M, Keren O, Sarne Y, (2011). Pre- and post-conditioning treatment with an ultra-low dose of Δ9- tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage. Behav Brain Res 220: 194-201.
7. Bash R, Rubovitch V, Gafni M, Sarne Y, (2003). The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12: 39-44. (Pubitemid 37490491)
8. Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Cote R, et al,. (2000). Seizures after stroke: a prospective multicenter study. Arch Neurol 57: 1617-1622.
9. Block RI, (1996). Does heavy marijuana use impair human cognition and brain function? JAMA 275: 560-561. (Pubitemid 26061434)
10. Bologov A, Gafni M, Keren O, Sarne Y, (2011). Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro. Cell Mol Neurobiol 31: 195-202.
11. Bouaboula M, Bianchini L, McKenzie FR, Pouyssegur J, Casellas P, (1999). Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett 449: 61-65. (Pubitemid 29182672)
12. Braida D, Pozzi M, Sala M, (2000). CP 55 940 protects against ischemia-induced electroencephalographic flattening and hyperlocomotion in Mongolian gerbils. Neurosci Lett 296: 69-72.
13. Carracedo A, Geelen MJ, Diez M, Hanada K, Guzman M, Velasco G, (2004). Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 380: 435-440. (Pubitemid 38788115)
14. Caulfield MP, Brown DA, (1992). Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106: 231-232.
15. Chan GC, Hinds TR, Impey S, Storm DR, (1998). Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 18: 5322-5332.
16. Chaperon F, Thiebot MH, (1999). Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13: 243-281. (Pubitemid 30265251)
17. Charriaut-Marlangue C, Aggoun-Zouaoui D, Represa A, Ben-Ari Y, (1996). Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Trends Neurosci 19: 109-114.
18. Christensen J, Pedersen MG, Pedersen CB, Sidenius P, Olsen J, Vestergaard M, (2009). Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study. Lancet 373: 1105-1110.
19. Clark RE, Broadbent NJ, Squire LR, (2005). Hippocampus and remote spatial memory in rats. Hippocampus 15: 260-272. (Pubitemid 40458425)
20. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF, (2003). Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci 23: 3916-3923. (Pubitemid 36958497)
21. Das M, Das DK, (2008). Molecular mechanism of preconditioning. IUBMB Life 60: 199-203.
22. Davis WM, Moreton JE, King WT, Pace HB, (1972). Marihuana on locomotor activity: biphasic effect and tolerance development. Res Commun Chem Pathol Pharmacol 3: 29-35.
23. De Reuck J, Claeys I, Martens S, Vanwalleghem P, Van Maele G, Phlypo R, et al,. (2006). Computed tomographic changes of the brain and clinical outcome of patients with seizures and epilepsy after an ischaemic hemispheric stroke. Eur J Neurol 13: 402-407.
24. Dere E, Huston JP, De Souza Silva MA, (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31: 673-704. (Pubitemid 46670336)
25. Derkinderen P, Ledent C, Parmentier M, Girault JA, (2001). Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem 77: 957-960. (Pubitemid 32466793)
26. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, et al,. (2003). Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23: 2371-2382. (Pubitemid 36368926)
27. Di Marzo V, (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455. (Pubitemid 351649182)
28. Dirnagl U, Simon RP, Hallenbeck JM, (2003). Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26: 248-254. (Pubitemid 36556155)
29. Dirnagl U, Becker K, Meisel A, (2009). Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 8: 398-412.
30. Doble A, (1999). The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 81: 163-221. (Pubitemid 29094735)
31. Downer EJ, Campbell VA, (2010). Phytocannabinoids, CNS cells and development: a dead issue? Drug Alcohol Rev 29: 91-98.
32. Downer EJ, Fogarty MP, Campbell VA, (2003). Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140: 547-557. (Pubitemid 37330499)
33. Downer EJ, Gowran A, Campbell VA, (2007a). A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res 1175: 39-47. (Pubitemid 47513013)
34. Downer EJ, Gowran A, Murphy AC, Campbell VA, (2007b). The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurons. Eur J Pharmacol 564: 57-65. (Pubitemid 46946853)
35. Doyle KP, Simon RP, Stenzel-Poore MP, (2008). Mechanisms of ischemic brain damage. Neuropharmacology 55: 310-318.
36. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, et al,. (1999). Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142: 295-301. (Pubitemid 29200157)
37. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A, (2003). Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41: 161-168. (Pubitemid 36262193)
38. Fehr KA, Kalant H, LeBlanc AE, (1976). Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science 192: 1249-1251.
39. Fernandez-Ruiz J, Pazos MR, Garcia-Arencibia M, Sagredo O, Ramos JA, (2008). Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 286: S91-S96.
40. Fletcher JM, Page JB, Francis DJ, Copeland K, Naus MJ, Davis CM, et al,. (1996). Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 53: 1051-1057. (Pubitemid 26384674)
41. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A, (2010). Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224: 37-47.
42. Galve-Roperh I, Sanchez C, Cortes ML, del Pulgar TG, Izquierdo M, Guzman M, (2000). Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 313-319. (Pubitemid 30148624)
43. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M, (2007). The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13: 109-114. (Pubitemid 46524315)
44. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M, (2008). Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14: 2279-2288.
45. Gidday JM, (2006). Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7: 437-448. (Pubitemid 44012284)
46. Glass M, Felder CC, (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
47. Golub MS, Sassenrath EN, Chapman LF, (1982). An analysis of altered attention in monkeys exposed to delta-9-tetrahydrocannabinol during development. Neurobehav Toxicol Teratol 4: 469-472. (Pubitemid 12023279)
48. Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G, (2002). Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277: 36527-36533.
49. Gross ER, Gross GJ, (2006). Ligand triggers of classical preconditioning and postconditioning. Cardiovasc Res 70: 212-221.
50. Guzman M, (2003). Neurons on cannabinoids: dead or alive? Br J Pharmacol 140: 439-440. (Pubitemid 37330487)
51. Guzman M, Sanchez C, Galve-Roperh I, (2002). Cannabinoids and cell fate. Pharmacol Ther 95: 175-184. (Pubitemid 35232135)
52. Hampson AJ, Grimaldi M, (2001). Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 13: 1529-1536. (Pubitemid 32423339)
53. Hampson AJ, Grimaldi M, Axelrod J, Wink D, (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95: 8268-8273. (Pubitemid 28326102)
54. Hausenloy DJ, Yellon DM, (2008). Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 79: 377-386.
55. Hausenloy DJ, Yellon DM, (2009). Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204: 334-341.
56. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Ogata A, Fujioka M, et al,. (2007). Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia. Life Sci 80: 1466-1471. (Pubitemid 46399748)
57. Hillard CJ, Muthian S, Kearn CS, (1999). Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459: 277-281. (Pubitemid 29475047)
58. Howlett AC, (1995). Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35: 607-634.
59. Howlett AC, Blume LC, Dalton GD, (2010). CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 17: 1382-1393.
60. Hu B, Wang Q, Chen Y, Du J, Zhu X, Lu Y, et al,. (2010). Neuroprotective effect of WIN 55,212-2 pretreatment against focal cerebral ischemia through activation of extracellular signal-regulated kinases in rats. Eur J Pharmacol 645: 102-107.
61. Huang LT, Yang SN, Liou CW, Hung PL, Lai MC, Wang CL, et al,. (2002). Pentylenetetrazol-induced recurrent seizures in rat pups: time course on spatial learning and long-term effects. Epilepsia 43: 567-573. (Pubitemid 34627714)
62. Ishimaru H, Nabeshima T, Katoh A, Suzuki H, Fukuta T, Kameyama T, (1991). Effects of successive carbon monoxide exposures on delayed neuronal death in mice under the maintenance of normal body temperature. Biochem Biophys Res Commun 179: 836-840.
63. Kellogg R, Mackie K, Straiker A, (2009). Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons. J Neurophysiol 102: 1160-1171.
64. Kitagawa K, Matsumoto M, Kuwabara K, Tagaya M, Ohtsuki T, Hata R, et al,. (1991). 'Ischemic tolerance' phenomenon detected in various brain regions. Brain Res 561: 203-211.
65. Lamberty Y, Klitgaard H, (2000). Consequences of pentylenetetrazole kindling on spatial memory and emotional responding in the rat. Epilepsy Behav 1: 256-261.
66. Landfield PW, Cadwallader LB, Vinsant S, (1988). Quantitative changes in hippocampal structure following long-term exposure to delta 9- tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443: 47-62. (Pubitemid 18062771)
67. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J, (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96-107. (Pubitemid 40544727)
68. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM, (2000). Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 877: 407-410.
69. Leker RR, Gai N, Mechoulam R, Ovadia H, (2003). Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34: 2000-2006. (Pubitemid 36944797)
70. McHale S, Hunt N, (2008). Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol 23: 409-415.
71. Mackie K, Hille B, (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825-3829.
72. Maneuf YP, Brotchie JM, (1997). Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120: 1397-1398. (Pubitemid 27192426)
73. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, et al,. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13: 492-497. (Pubitemid 46559830)
74. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C, (2002). Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80: 448-456. (Pubitemid 36383028)
75. Matochik JA, Eldreth DA, Cadet JL, Bolla KI, (2005). Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77: 23-30. (Pubitemid 39656096)
76. Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E, (2003). Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 989: 99-111. (Pubitemid 37281406)
77. Maurice T, Phan VL, Noda Y, Yamada K, Privat A, Nabeshima T, (1999). The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (sigma) receptor ligands involves both sigma1 and sigma2 sites. Br J Pharmacol 127: 335-342. (Pubitemid 29245669)
78. Meunier J, Ieni J, Maurice T, (2006). Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther 317: 1307-1319. (Pubitemid 43764137)
79. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM, (2005). Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci 28: 189-194. (Pubitemid 39656022)
80. Moranta D, Esteban S, Garcia-Sevilla JA, (2007). Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: short-term regulation by intrinsic and extrinsic pathways. J Neurosci Res 85: 656-667.
81. Murry CE, Jennings RB, Reimer KA, (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136. (Pubitemid 17174962)
82. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, et al,. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995. (Pubitemid 29173995)
83. Obrenovitch TP, (2008). Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 88: 211-247.
84. Okada M, Urae A, Mine K, Shoyama Y, Iwasaki K, Fujiwara M, (1992). The facilitating and suppressing effects of delta 9-tetrahydrocannabinol on the rise in intrasynaptosomal Ca2+ concentration in rats. Neurosci Lett 140: 55-58.
85. Ozaita A, Puighermanal E, Maldonado R, (2007). Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102: 1105-1114. (Pubitemid 47174245)
86. Pacher P, Batkai S, Kunos G, (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462. (Pubitemid 44394908)
87. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al,. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531. (Pubitemid 32938751)
88. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al,. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
89. Pertwee RG, (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74: 129-180. (Pubitemid 27337346)
90. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
91. Pignataro G, Meller R, Inoue K, Ordonez AN, Ashley MD, Xiong Z, et al,. (2008). In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab 28: 232-241. (Pubitemid 351161298)
92. Pitkanen A, Immonen RJ, Grohn OH, Kharatishvili I, (2009). From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 50 (Suppl. 2): 21-29.
93. Pope HG, Jr, Yurgelun-Todd D, (1996). The residual cognitive effects of heavy marijuana use in college students. JAMA 275: 521-527. (Pubitemid 26061426)
94. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, et al,. (2008). Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33: 1113-1126. (Pubitemid 351367534)
95. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML, (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913. (Pubitemid 40289395)
96. Roloff AM, Thayer SA, (2009). Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol 75: 892-900.
97. Rubino T, Forlani G, Vigano D, Zippel R, Parolaro D, (2004). Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25: 355-362. (Pubitemid 38366401)
98. Rubovitch V, Gafni M, Sarne Y, (2002). The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101: 93-102. (Pubitemid 34465565)
99. Rubovitch V, Gafni M, Sarne Y, (2004). The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120: 138-144. (Pubitemid 38115810)
100. Rueda D, Galve-Roperh I, Haro A, Guzman M, (2000). The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58: 814-820.
101. Rutten A, van Albada M, Silveira DC, Cha BH, Liu X, Hu YN, et al,. (2002). Memory impairment following status epilepticus in immature rats: time-course and environmental effects. Eur J Neurosci 16: 501-513. (Pubitemid 35471869)
102. Sankar R, Shin DH, Liu H, Mazarati A, Pereira de Vasconcelos A, Wasterlain CG, (1998). Patterns of status epilepticus-induced neuronal injury during development and long-term consequences. J Neurosci 18: 8382-8393. (Pubitemid 28465013)
103. Sarne Y, Keren O, (2004). Are cannabinoid drugs neurotoxic or neuroprotective? Med Hypotheses 63: 187-192. (Pubitemid 38968713)
104. Sarne Y, Mechoulam R, (2005). Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4: 677-684. (Pubitemid 41782629)
105. Scallet AC, (1991). Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40: 671-676.
106. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M, (2010). Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 160: 747-761.
107. Senn R, Keren O, Hefetz A, Sarne Y, (2008). Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice. Pharmacol Biochem Behav 88: 230-237. (Pubitemid 350116250)
108. Shen M, Thayer SA, (1998). Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54: 459-462. (Pubitemid 28442938)
109. Shen M, Piser TM, Seybold VS, Thayer SA, (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16: 4322-4334. (Pubitemid 26243028)
110. Shohami E, Mechoulam R, (2000). Dexanabinol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev Res 50: 211-215.
111. Shouman B, Fontaine RH, Baud O, Schwendimann L, Keller M, Spedding M, et al,. (2006). Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol 148: 442-451. (Pubitemid 43882080)
112. Sinor AD, Irvin SM, Greenberg DA, (2000). Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278: 157-160. (Pubitemid 30009481)
113. Solowij N, Michie PT, Fox AM, (1991). Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40: 683-688.
114. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al,. (2002). Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123-1131. (Pubitemid 34252081)
115. Stiglick A, Llewellyn ME, Kalant H, (1984). Residual effects of prolonged cannabis treatment on shuttle-box avoidance in the rat. Psychopharmacology (Berl) 84: 476-479. (Pubitemid 15179664)
116. Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K, et al,. (1997). Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J Biochem (Tokyo) 122: 890-895. (Pubitemid 27474963)
117. Sulcova E, Mechoulam R, Fride E, (1998). Biphasic effects of anandamide. Pharmacol Biochem Behav 59: 347-352. (Pubitemid 28072727)
118. Taylor DA, Fennessy MR, (1977). Biphasic nature of the effects of Δ9-tetrahydrocannabinol on body temperature and brain amines of the rat. Eur J Pharmacol 46: 93-99. (Pubitemid 8212640)
119. Tonini R, Ciardo S, Cerovic M, Rubino T, Parolaro D, Mazzanti M, et al,. (2006). ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci 26: 5810-5818. (Pubitemid 44315274)
120. Troy CM, Friedman JE, Friedman WJ, (2002). Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. J Biol Chem 277: 34295-34302.
121. Tselnicker I, (2005). A single ultra-low dose of Δ9- tetrahydrocannabinol causes long-term cognitive deficits in mice. In M.Sc. Thesis.
122. Tselnicker I, Keren O, Hefetz A, Pick CG, Sarne Y, (2007). A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. Neurosci Lett 411: 108-111. (Pubitemid 44820686)
123. Twitchell W, Brown S, Mackie K, (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78: 43-50. (Pubitemid 27318909)
124. Valjent E, Pages C, Rogard M, Besson MJ, Maldonado R, Caboche J, (2001). Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur J Neurosci 14: 342-352. (Pubitemid 32777639)
125. van der Stelt M, Di Marzo V, (2005). Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 7: 37-50. (Pubitemid 41278188)
126. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K, (2001a). Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21: 6475-6479. (Pubitemid 32781091)
127. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, et al,. (2001b). Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21: 8765-8771. (Pubitemid 33054840)
128. Verrico CD, Jentsch JD, Roth RH, Taylor JR, (2004). Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharmacology 29: 522-529. (Pubitemid 38365928)
129. Viscomi MT, Oddi S, Latini L, Bisicchia E, Maccarrone M, Molinari M, (2010). The endocannabinoid system: a new entry in remote cell death mechanisms. Exp Neurol 224: 56-65.
130. Wagner JA, Jarai Z, Batkai S, Kunos G, (2001). Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203-210. (Pubitemid 32614159)
131. Wang P, Wang WP, Sun Z, Wang HX, Yan L, Fan YH, (2008). Impaired spatial learning related with decreased expression of calcium/calmodulin-dependent protein kinase II alpha and cAMP-response element binding protein in the pentylenetetrazol-kindled rats. Brain Res 1238: 108-117.
132. Whishaw IQ, Tomie JA, (1996). Of mice and mazes: similarities between mice and rats on dry land but not water mazes. Physiol Behav 60: 1191-1197. (Pubitemid 26389047)
133. Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A, (2009). The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 56: 329-341.
134. Zemke D, Smith JL, Reeves MJ, Majid A, (2004). Ischemia and ischemic tolerance in the brain: an overview. Neurotoxicology 25: 895-904. (Pubitemid 39335582)
135. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF, (2007). Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27: 1387-1396. (Pubitemid 46985356)
136. Zhao H, (2009). Ischemic postconditioning as a novel avenue to protect against brain injury after stroke. J Cereb Blood Flow Metab 29: 873-885.
137. Zhao ZQ, Vinten-Johansen J, (2006). Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 70: 200-211.